Pipeline
Atebimetinib (IMM-1-104)
Pancreatic (PDAC)
Discovery
IND-enabling
Phase 1
Phase 2
Phase 3
Combination
1L, Atebimetinib
+ mGem/nab-Pac
Combination
1L, Atebimetinib
+ mFOLFIRINOX
Monotherapy
2L (or 1L)
Melanoma (MEL)
Discovery
IND-enabling
Phase 1
Phase 2
Phase 3
Monotherapy
2L, 3L, post-IO (or 1L)
Combination
(Planned)
2L, 3L, Atebimetinib
+ PD-1
Combination
(Planned)
2L, 3L, Atebimetinib
+ BRAFi
Non-small Cell Lung Cancer (NSCLC)
Discovery
IND-enabling
Phase 1
Phase 2
Phase 3
Monotherapy
2L, 3L, post-IO
Combination
(Planned)
2L, 3L, Atebimetinib
+ G12Ci
Combination*
(Planned)
1L, Atebimetinib
+ PD-1
*Clinical supply agreement with Regeneron Pharmaceuticals
Additional Oncology Programs
Solid Tumors
Discovery
IND-enabling
Phase 1
Phase 2
Phase 3
Monotherapy
IMM-6-415
Monotherapy
Multiple DCI Programs
More than half of all tumors rely on inappropriate activation of the RAS/RAF/MEK pathway, yet existing drugs targeting this pathway are limited by toxicity or are narrowly focused on subpopulations with specific mutations. Immuneering’s novel drug candidates are designed to improve tolerability by modulating cell signaling dynamics to selectively impact tumor cells and expand indications for a broader population of cancer patients.
Oncology – Select Therapies
Atebimetinib (IMM-1-104)
Our lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. (NCT05585320)
IMM-6-415
IMM-6-415 is an oral, twice-daily deep cyclic inhibitor of MEK currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. (NCT06208124)
Expanded Access Policy
Expanded access, sometimes also referred to as “compassionate use,” is a potential alternative for patients to receive investigational treatments outside of a clinical trial. According to FDA, expanded access may be applicable when all the following apply:
- Patients have a serious or immediately life-threatening disease or condition;
- There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition;
- Patient enrollment in a clinical trial is not possible;
- Potential patient benefit justifies the potential risks of treatment; and
- Providing the investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication.
At this time, expanded access is not available for any of our product candidate programs. We aim to provide investigational treatments when they have the greatest potential to benefit patients. Our lead product candidates IMM-1-104 and IMM-6-415 are currently still in the early stages of development, and clinical trials are ongoing to understand, among other things, the potential safety and efficacy of these investigational treatments. We believe that participation in a clinical trial is currently the most appropriate way for a patient to receive one of our product candidates in development. Clinical trials for our programs are provided above, and here hyperlinked to clinicaltrials.gov for more information. We will periodically assess the potential appropriateness of expanded access in the future, and may revise our policy as the development of our product candidate programs progresses.
If you have additional questions regarding expanded access or participation in a clinical trial, please speak with your physician or contact clinicaltrials@immuneering.com.
